{
    "id": 27522,
    "fullName": "MTAP loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "MTAP loss indicates loss of the MTAP gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4507,
        "geneSymbol": "MTAP",
        "terms": [
            "MTAP",
            "BDMF",
            "c86fus",
            "DMSFH",
            "DMSMFH",
            "HEL-249",
            "LGMBF",
            "MSAP"
        ]
    },
    "variant": "loss",
    "createDate": "03/16/2018",
    "updateDate": "03/16/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 19991,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MTAP deficiency was associated with sensitivity to GSK3368715 in melanoma cell lines in culture (PMID: 31257072).",
            "molecularProfile": {
                "id": 29040,
                "profileName": "MTAP loss"
            },
            "therapy": {
                "id": 9261,
                "therapyName": "GSK3368715",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17642,
                    "pubMedId": 31257072,
                    "title": "Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31257072"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19990,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MTAP deficiency was associated with sensitivity to GSK3368715 in pancreatic cancer cell lines in culture, and only MTAP-deficient cell lines demonstrated a cytotoxic response to GSK3368715 treatment (PMID: 31257072).",
            "molecularProfile": {
                "id": 29040,
                "profileName": "MTAP loss"
            },
            "therapy": {
                "id": 9261,
                "therapyName": "GSK3368715",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17642,
                    "pubMedId": 31257072,
                    "title": "Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31257072"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19992,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MTAP deficiency was associated with sensitivity to GSK3368715 in lymphoma cell lines in culture (PMID: 31257072).",
            "molecularProfile": {
                "id": 29040,
                "profileName": "MTAP loss"
            },
            "therapy": {
                "id": 9261,
                "therapyName": "GSK3368715",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17642,
                    "pubMedId": 31257072,
                    "title": "Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31257072"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29040,
            "profileName": "MTAP loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}